Section 'Sub' Navigation:
Dr. Jeremiah Momper
Jeremiah D. Momper, Pharm.D., Ph.D.
Assistant Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Research Summary: Clinical Pharmacology
Dr. Momper’s research is focused on mechanistically understanding alterations in drug disposition and response in special populations. Current research directions include the application of novel clinical pharmacology tools, such as physiologically based pharmacokinetic modeling, to support scientific decision making during pediatric drug development. In addition, Dr. Momper directs the Drug Metabolism and Pharmacokinetics (DMPK) research core lab which provides screening tools for in vitro ADME and in vivo pharmacokinetics.
Pharm.D. (2006) University of Pittsburgh; Ph.D. in Pharmaceutical Sciences (2011) University of Pittsburgh; Commissioner’s Fellowship (2011-2013) Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- Course Director, Clinical Pharmacokinetics (SPPS 226)
- Biopharmaceutics (SPPS 224)
- Dosage Forms and Delivery Systems (SPPS 225)
- Renal System I (SOMC 225)
Key Contributions to Pharmaceutical Sciences
- Characterized the population pharmacokinetics and dosing requirements of fluconazole for prophylaxis of invasive candidiasis in premature infants.
- Described the pharmacokinetics of cidofovir in kidney transplant patients with BK virus infection.
- Established the role of allometric scaling during drug development for the prediction of clearance and associated variability in pediatric populations.
Selected Recent Publications (view more)
- Momper JD, et al. (2013). Pharmacokinetics of low- dose cidofovir in kidney transplant recipients with BK virus infection. Transpl Infect Dis. 15:34-41.
- Edginton AN, et al. (2013). The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin Pharmacokinet. 52:693-703.
- Momper JD et al. (2013). Applications of population pharmacokinetics for pediatric drug development. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, eds. Pediatric Drug Development. 2nd ed. Hoboken, NJ: Wiley-Blackwell.
- Momper JD, et al. (2014). Drug development for pediatric neurogenic bladder dysfunction: Dosing, endpoints, and study design. J Clin Pharmacol. 54:1239-46
- Momper JD, Wagner JA (2014). Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development. Clin Pharmacol Ther. 95:138-40
- Momper JD, et al. (2015). Failed pediatric drug development trials. Clin Pharmacol Ther. 98:245-51.
- Momper JD, Tsunoda SM, Ma JD. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans. (2016). J Clin Pharmacol. 56:S82-98.
- Momper JD, et al. (2016). Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams. Antimicrob Agents Chemother, 60:5539-45.
Potential Collaborative Programs with the Pharmaceutical Industry
- Model based pediatric drug development and simulation
- Clinical pharmacology protocol design and data ￼analysis
- Pharmacokinetic studies in renal impairment and transplantation